A readily accessible and affordable method for the identification of individuals with KSHV and other co-infections would allow clinicians to factor this information into clinical decision-making, potentially starting ART at higher CD4 cell counts in areas where this is not yet routine despite updated guidelines for universal treatment, or increasing KS surveillance for earlier detection as strategies to reduce morbidity and mortality. This evidence concerns the gene CD4 and coinfection.